louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05340699: Safety and Efficacy of Defocus Distributed Multi-point Lens in Myopia Control
Official title: Safety and Efficacy of Defocus Distributed Multi-point Lens in Myopia Control
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Myopia
Lead sponsor: Tianjin Eye Hospital
Sponsor class: OTHER
First posted: 2022-04-22
Enrollment: 168
Sex: ALL
Minimum age (years): 6
Maximum age (years): 13
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluate the safety and effectiveness of experimental group by comparing with the control group

Detailed description: Compared the experimental group with the control group,the safety and effectiveness of DDM lens in mtopia control will be evaluated.

Eligibility criteria: Inclusion Criteria:

* Aged 6-13,with written consent of his/her guardian,regardless of gender;
* Objective cycloplegic spherical equivalent refractive between -1.00D and 5.00D,and best corrected vision acuity of right and left eyes are better than or equal to 1.0;
* Astigmatism less than or equal to -1.50D;
* Voluntarily participate in the clinical trial and sign the informed consent.

Exclusion Criteria:

* Those with a history of ocular trauma or intraocular surgery;
* Clinical significant slit-lamp findings;
* Abnormal IOP(\<10 mmHg , \>21 mmHg or difference between two eyes \>5mmHg);
* Patient with other eye diseases,such as uveitis and other inflammation,glaucoma,cataract,fundus disease,eye tumors,eye trauma,strabismus and any lesions that affect vision function;
* Patient with systemic diseases causing immunosuppression,such as acute or chronic sinusitis,diabetes,Down syndrome,rheumatoid arthritis,psychosis and other conditions that the investigator considers inappropriate for wearing glasses;
* Those who have participated in other drug clinical trials within 3 months;
* Only one eye meets the inclusion criteria;
* Those who cannot have regular eye examinations;
* Those who have been involved in any myopia control clinical trials,previously used or are using RGP,contact lens and glasses or atropine drugs to control myopia in the past year;
* The candidates determined by the investigator are not eligible.

Primary outcomes:
measure: Changes in Objective cycloplegic refractive
timeFrame: baseline, 12 months
measure: Changes in Axial Length
timeFrame: baseline, 12 months
Secondary outcomes:
measure: Changes in Objective cycloplegic refractive
timeFrame: baseline, 6 months，18 months and 24 months
measure: Changes in Axial length
timeFrame: baseline, 6 months，18 months and 24 months
measure: Changes in amplitude of accommodation
timeFrame: baseline, 6 months，18 months and 24 months
measure: Changes in near point of convergence
timeFrame: baseline, 6 months，18 months and 24 months
Other outcomes:
Locations:
city: Tianjin
country: China
facility: Tianjin Eye Hospital
Study officials:
affiliation: Tianjin Eye Hospital, Tianjin,China
name: Xiaoqin Chen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01245699: MIHS Emergency Department CPR Quality Improvement Project
Official title: MIHS Emergency Department CPR Quality Improvement Project
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiac Arrest
Keywords: Cardiac arrest, CPR, quality improvement
Lead sponsor: Valleywise Health
Sponsor class: OTHER
First posted: 2010-11-22
Enrollment: 115
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Chest Compression before and after RealCPRHelp
Primary purpose: TREATMENT

Brief summary: The investigators will quantify the quality of chest compressions provided in the Emergency Department and determine whether the quality of chest compressions is related to patient outcome. The quality of chest compressions and patient outcomes will be assessed both before and after the introduction of audiovisual feedback in real time.

Detailed description: The Emergency Department will be using E-series unit manufactured by ZOLL Medical Group (Chelmsford, MA). These units are equipped with an accelerometer-based system that allows for measurement of chest compression depth and rate. These units are also equipped with RealCPRHelp, and FDA-approved technology that provides real-time audiovisual feedback to providers on the quality of chest compressions.

In the first phase of the project, the ED providers will utilize the E-series units to treat all patients requiring chest compressions.

Eligibility criteria: Inclusion Criteria:

* 18 years old or older

Exclusion Criteria:

* less than 18 years old

Primary outcomes:
measure: CPR Quality-compression Depth
timeFrame: during CPR
measure: CPR Quality-percent of >51mm Compressions
timeFrame: during CPR
measure: CPR Quality
timeFrame: during CPR
measure: CPR Quality-compression Fraction
timeFrame: During CPR
measure: CPR Quality-Chest Compression Rate
timeFrame: During CPR
measure: CPR Quality- Pre-shock Pause
timeFrame: During CPR
Secondary outcomes:
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Maricopa Integrated Health System
state: Arizona
Study officials:
affiliation: Valleywise Health
name: Bentley J Bobrow, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bobrow BJ, Clark LL, Ewy GA, Chikani V, Sanders AB, Berg RA, Richman PB, Kern KB. Minimally interrupted cardiac resuscitation by emergency medical services for out-of-hospital cardiac arrest. JAMA. 2008 Mar 12;299(10):1158-65. doi: 10.1001/jama.299.10.1158.
Clinical trial NCT03156699: The Incidence, Effect and Persistence of Fragmented-QRS, in Patients Presenting With ST-Elevation Myocardial Infarction
Official title: The Incidence, Effect and Persistence of Fragmented-QRS, in Patients Presenting With ST-Elevation Myocardial Infarction
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: ST Elevation Myocardial Infarction
Lead sponsor: The Royal Wolverhampton Hospitals NHS Trust
Sponsor class: OTHER_GOV
First posted: 2017-05-17
Enrollment: 64
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 100 STEMI patients treated with primary PCI.

Brief summary: This study will assess the incidence, effect and persistence of F-QRS (Fragmented-QRS) in STEMI (ST-elevation Myocardial Infarction) patients post-PCI (percutaneous coronary intervention). The aim is to add to the existing research field surrounding F-QRS. It is hypothesised that patients with F-QRS present on the surface ECG, following PCI, will have incurred a higher degree of damage. As a result, it is hypothesised that these patients will have reduced LV (left-ventricular) systolic function, increased incidence of regional wall motion abnormalities (RWMAs), and increased troponin levels on admission. This study will additionally look for correlations between F-QRS and culprit vessels. To our knowledge there is minimal research regarding this.

Detailed description: This is a Physiological - Retrospective data collection from STEMI patients. Data from 100 STEMI patients treated with primary PCI will be extracted.

Data will be collected from presentation / initial admission, 6-week post-MI (Myocardial Infarction) clinic and 6 month post-MI clinic from the hospital system at New Cross Hospital. Data from admission includes; 12-lead ECG, echo reports and blood test results. Additionally, the 12-lead ECGs undertaken at 6-week and 6-months will be assessed for the presence of F-QRS.

Eligibility criteria: Inclusion Criteria:

* Look back to data at least 12 months old in order to ensure 6-week and 6-month follow up data is available. The inclusion criteria will be patients that presented with STEMI and were treated with primary PCI.

Exclusion Criteria:

* From the cath lab reports and clinical letters exclusions apply to patients that did not present with STEMI. In addition, patients that were not treated with primary PCI, or patients that deceased prior, during or post procedure (during hospitalization).

Primary outcomes:
measure: F-QRS measurements
timeFrame: Over 6 months
Secondary outcomes:
measure: Left ventricular ejection fraction (LVEF)
timeFrame: Over 6 months
measure: T-Troponin tests
timeFrame: Over 6 months
Other outcomes:
Locations:
city: Wolverhampton
country: United Kingdom
facility: New Cross Hospital
state: West Midlands
Study officials:
affiliation: The Royal Wolverhampton NHS Trust
name: Joseph Kelly
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02397642: Dual Trigger Versus Booster Dose of HCG
Official title: Dual Trigger Versus Booster Dose of HCG on Ovum Pickup Day in Antagonist IVF/ICSI Cycles Triggered With GnRH Agonist in High Responder Females to Salvage the Luteal Phase
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infertility
Lead sponsor: Cairo University
Sponsor class: OTHER
Collaborators: name: Nile Ivf Center, Cairo, Egypt
name: Adam International Hospital
First posted: 2015-03-25
Enrollment: 200
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 37
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To salvage the luteal phase and improve pregnancy rate in antagonist IVF/ICSI cycles triggered with GnRH agonist. Two strategies are compared dual trigger with GnRH agonist plus 1000 IU of HCG or triggering with GnRH and giving a booster dose of HCG (1500 IU) on the day of ovum pickup.


Eligibility criteria: Inclusion Criteria:

* High responder females undergoing antagonist protocol IVF/ICSI cycle
* More than 14 MII oocytes
* Estradiol more than 3500 pg/ml on day of trigger

Exclusion Criteria:

* Any other protocol
* Normal or poor responders

Primary outcomes:
measure: Clinical pregnancy rate
timeFrame: 1 year
Secondary outcomes:
measure: OHSS rate
timeFrame: 1 year
Other outcomes:
measure: Chemical pregnancy rate
timeFrame: 1 year
measure: Early miscarriage rate
timeFrame: 1 year
measure: Ongoing pregnancy rate
timeFrame: 1 year
measure: Live birth rate
timeFrame: 1 year
Locations:
city: Cairo
country: Egypt
facility: IVF centre, Obstetrics and Gynaecology Department, Cairo University Hospitals (Kasr EL Aini)
city: Giza
country: Egypt
facility: Adam International hospital
city: Giza
country: Egypt
facility: Nile IVF center
Study officials:
affiliation: Cairo University
name: Sarwat Ahwany, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05771142: Evaluation of an Innovative Smart T-shirt Capable to Monitor ECG Signal and Related Parameters Through the Comparison With a Holter ECG and a Smartwatch
Official title: Evaluation of an Innovative Smart T-shirt Capable to Monitor ECG Signal and Related Parameters Through the Comparison With a Holter ECG and a Smartwatch
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cardiac Arrhythmias
Keywords: smart t-shirt
wearable
electrocardiogram
Lead sponsor: University of Bologna
Sponsor class: OTHER
Collaborators: name: AccYouRate S.p.A.
First posted: 2023-03-16
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study will be conducted in subjects with heart rhythm pathologies or under assessment of possible heart rhythm pathologies.

Brief summary: Evaluation of an innovative smart t-shirt capable to monitor ECG signal and related parameters through the comparison with a Holter ECG and a smartwatch

Detailed description: The primary purpose of this study is to evaluate the biosignal (ECG) acquisition features of the smart t-shirt, developed by University of Bologna in collaboration with AccYouRate S.p.A., comparing it with a standard Holter ECG. Secondly, the study wants to compare the parameters related to ECG signal calculated by the smart t-shirt with those calculated by commercial smartwatches.

Eligibility criteria: Inclusion Criteria:

1. Subjects agree to participate in the study and having dated and signed the informed consent form,
2. Subjects who have the capability to communicate, to make themselves understood, and to comply with the study's requirements,
3. Male or female aged ≥ 18 years and ≤ 90 years old,
4. Subjects with Cardiac electrophysiological (heart rhythm) pathologies or under screening for the assessment of possible cardiac electrophysiological pathologies.

Exclusion Criteria:

1. Subjects that for different reasons have difficulties to wear the sensorized t-shirt or the alternative sensorized chest band: Movement's impairments; Dermatological reaction to t-shirt fabric or materials,
2. Any medical or surgical condition that would limit the patient adhesion to the study protocol,
3. Severe obesity and sever underweight,
4. Subject that are not able to understand the scope of the study.

Primary outcomes:
measure: Electrocardiogram (ECG): Heart rate (beats per minute)
timeFrame: 24 hours
measure: Electrocardiogram (ECG): RR interval (seconds)
timeFrame: 24 hours
measure: Electrocardiogram (ECG): Qualitative distinction of P-waves, QRS-complexes, T-waves, and noise levels
timeFrame: 24 hours
Secondary outcomes:
measure: Electrocardiogram (ECG): Heart rate (beats per minute)
timeFrame: 24 hours
Other outcomes:
Locations:
city: Bologna
country: Italy
facility: Policlinico Sant'Orsola Malpighi - University of Bologna
Study officials:
References:
Clinical trial NCT06887842: Posterior Nasal Nerve Neurectomy for Treatment of Intractable Allergic Rhinitis
Official title: Posterior Nasal Nerve Surgical Resection Versus Radiofrequency Ablation Versus Surface Coblation for Treatment of Intractable Allergic Rhinitis
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Intractable Allergic Rhinitis
Lead sponsor: Kafrelsheikh University
Sponsor class: OTHER
First posted: 2025-03-20
Enrollment: 84
Sex: ALL
Minimum age (years): 16
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This study aims to compare the outcomes of posterior nasal nerve neurectomy in patients with resistant Allergic rhinitis by using three different methods ( surgical resection vs radiofrequency ablation vs surface coblation ) through assesment of functional outcomes, postoperative complications, and impacts on quality of life.


Eligibility criteria: Inclusion Criteria:

* Patients aged 16 to 65 years, fit for surgery, diagnosed as moderate to severe persistent Allergic Rhinitis, as per the ARIA guidelines having 3 or more of the typical symptoms of Allergic Rhinitis including nasal discharge, repeated attacks of sneezing, nasal itching and nasal obstruction.

Exclusion Criteria:

* • Patients with Coexisting nasal pathologies that could influence the outcomes of the surgery like: chronic granulomatous diseases of the nose, nasal tumors, chronic sinsitis with or without nasal polyps, etc.

  * Patients who had used topical steroid nasal spray, oral or topical antihistamines, oral leukotriene antagonists, oral or tobical nasal decongestants in the last 2 weeks.
  * Immunocompromised patients, Systemic disease affecting prognosis such as diabetes mellitus, hypertension,chronic liver failure or heart failure.
  * Unwillingness for endoscopic surgery.
  * Patients younger than 18 years of age.
  * Patients who are unfit for general anesthesia.
  * Previous history of nasal surgery

Primary outcomes:
measure: Improvement of the four main symptoms (Sneezing ,itching , rhinorrhea ,nasal obstruction)
timeFrame: Evaluations will be scheduled for 2 weeks, one month, three months, and six months following surgery.
Secondary outcomes:
measure: postoperative complications eg. Bleeding, crustations etc, postoperative endoscopic score will be evaluated.
timeFrame: 2 weeks, 1M month after the procedure .
Other outcomes:
Locations:
city: Kafrelsheikh
country: Egypt
facility: kafrelsheikh University Hospitals
Study officials:
References:
citation: Ahilasamy N, Rajendran Dinesh K. [Endoscopic posterior nasal neurectomy]. J Laryngol Otol. 2019 Sep;133(9):825-829. doi: 10.1017/S002221511900166X. Epub 2019 Aug 23. Spanish.
Clinical trial NCT00480142: Controlled Release of Oxycodone 10 mg In Pre-Medication For The Post Operative Analgesia In Elective Laparoscopic Bilateral Inguinal Hernia And Elective Laparoscopic Cholecystectomy
Official title: Controlled Release of Oxycodone 10 mg In Pre-Medication For The Post Operative Analgesia In Elective Laparoscopic Bilateral Inguinal Hernia And Elective Laparoscopic Cholecystectomy : Prospective Double Blind, Randomized, Placebo-Controlled Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Elective Laproscopic Bilateral Inguinal Hernia
Elective Laproscopic Cholecystectomy
Lead sponsor: Kaplan Medical Center
Sponsor class: OTHER
First posted: 2007-05-30
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A Prospective Double Blind RCT: Controlled Release Oxycodone 10 mg On a 12 h Dosing Schedule Started With The Premedication ,Placebo Controlled Study,On Post Operative Analgesia Management in Laparoscopic Cholecystectomy and Laparoscopic Bilateral Inguinal Hernia (BIH).

CRO is indicated for the management of moderate to severe pain when a continuous,around the clock analgesic is needed for an extended period of time.Its safety and efficacy in the first 12-24 hours post operative has not been established.


Eligibility criteria: Inclusion Criteria:

* Local ethic committee approval
* Written informed consent
* ASA physical status I-III, scheduled for elective laparoscopic cholecystectomy and elective laparoscopic BIH

Exclusion Criteria:

* Difficulty in communication
* Allergy to oxycodone and/or morphine
* Allergy to local anesthetic
* History of alcohol and substance abuse
* Treated depression
* Chronic use of opioid or tramadol or NSAIDS
* Pregnancy
* Obstructive sleep apnea
* Anticipated fiber optic intubation
* Severe hepatic or renal impairment
* Weight \<50 kg or \> 100 kg
* Conversion to laparotomy
* Patient extubated in PACU.
* Any prior abdominal surgery

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Israel: Kaplan Hospital, Clalit Health Service
name: patricia grosman, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Israel:Clalit Health Service
name: Eli Mavor, MD
role: STUDY_CHAIR
affiliation: Isreal: Kaplan: Clalit Health Service
name: oscar liphshitz, MD
role: STUDY_DIRECTOR
affiliation: Israel: Kaplan: Clalit Health Service
name: Bella Almog, R.N MA
role: STUDY_DIRECTOR
References:
Clinical trial NCT00654342: Comparison Between ex Vivo and in Vivo Injection of Blue Dye in Sentinel Lymph Node Mapping for Colon Cancer
Official title: Comparison Between ex Vivo and in Vivo Injection of Blue Dye in Sentinel Lymph Node Mapping for Colon Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Sentinel Lymph Node Biopsy
Colon Cancer
Keywords: Sentinel lymph node-colon cancer
Lead sponsor: Chung-Ang University
Sponsor class: OTHER
First posted: 2008-04-08
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The technique of sentinel lymph node mapping in patients with colon cancer varies among reports, and the optimal method remain to be established. The purpose of this study was to determine the optimal injection technique for sentinel lymph node mapping for colon cancer.


Eligibility criteria: Inclusion Criteria:

* Stage I - III colon cancer patients

Exclusion Criteria:

* cancer located at the low rectum which were located within 10 cm of the dentate, recurrent or metastatic colon carcinoma, adjacent organ invasion tumor, prior chemotherapy or radiation, cancer with intestinal obstruction, past intestinal surgery

Primary outcomes:
measure: Accuracy & sensitivity of sentinel lymph node mapping
timeFrame: After confirmed pathological report
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Surgery, Chung-Ang university Hospital
Study officials:
References:
Clinical trial NCT01786642: Assessment of the Efficacy of Tracheal Oxygen Administration During Bronchoscopy - a Phase II Trial
Official title: Assessment of the Efficacy of Tracheal Oxygen Administration During Bronchoscopy - a Phase II Trial.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hypoxaemia
Lead sponsor: KU Leuven
Sponsor class: OTHER
First posted: 2013-02-08
Enrollment: 40
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: all patients referred for flexible bronchoscopy

Brief summary: The aim of the present study is to measure the time to correction of O2 saturation when in case of desaturation below 90%, O2 administration is switched from the nasal to the tracheal route at a similar flow rate.

Detailed description: The development of a flexible bronchoscope with a channel dedicated to O2 administration might allow optimization of the oxygen supplementation during bronchoscopy, which reduces the risk of per- and peri-procedural hypoxemia. The investigators will conduct a pilot study corroborating the hypothesis that tracheal supplementation of oxygen during flexible bronchoscopy is advantageous in comparison to nasal cannula supplementation.

The concept of our trial consists of a mono-centric observational study performed in the endoscopy suite of the Respiratory Division, University Hospitals Leuven. All patients will be given informed consent before inclusion.

The aim of the present study is to measure the time to correction of O2 saturation when in case of desaturation below 90%, O2 administration is switched from the nasal to the tracheal route at a similar flow rate.

Eligibility criteria: Inclusion Criteria:

* patients referred for flexible bronchoscopy

Exclusion Criteria:

* broncho-alveolar lavage
* endobronchial plugging

Primary outcomes:
measure: Time to correction of SpO2
timeFrame: procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: University hospitals leuven
Study officials:
affiliation: Universitaire Ziekenhuizen KU Leuven
name: Christophe Dooms, Md PhD
role: STUDY_DIRECTOR
References: